T

    Tarsus Pharmaceuticals Inc (TARS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $74.24
    +2.48 (+3.46%)

    Market Cap: $3.15B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(17/25)
    Avg Surprise
    +25.88%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.53
    Range$-1.91 - $-0.76
    5 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$-0.22+85.7%
    60d ago$-0.20+87.2%
    30d ago$-1.83-19.6%
    7d ago$-1.82-18.4%
    Current$-1.53
    Revenue Consensus
    $181M
    Range$179M - $185M
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.00
    Range$-0.20 - $0.50
    5 analysts
    Revenue Consensus
    $215M
    Range$208M - $224M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.00---
    Sep 26EST
    		-$-1.53---
    Jun 26
    		$-0.43$-0.21-104.76%Miss+10.4%
    Mar 26
    		$-0.16N/A+61.90%Beat+75.0%
    Dec 25
    		$-0.20$-0.08-139.23%Miss+66.7%
    Sep 25
    		$-0.30$-0.33+9.09%Beat+50.8%
    Jun 25
    		$-0.48$-0.36-33.33%Miss+42.2%
    Mar 25
    		$-0.64$-0.63-1.59%Miss+35.4%
    Dec 24
    		$-0.60$-0.82+26.44%Beat+54.2%
    Sep 24
    		$-0.61$-1.00+39.00%Beat+52.0%
    Jun 24
    		$-0.83$-0.80-3.75%Miss+29.1%
    Mar 24
    		$-0.99$-1.25+20.80%Beat-13.8%
    Dec 23
    		$-1.31$-1.36+3.68%Beat-167.3%
    Sep 23
    		$-1.27$-1.27+0.00%Beat-51.2%
    Jun 23
    		$-1.17$-1.02-14.71%Miss-431.8%
    Mar 23
    		$-0.87$-0.91+4.40%Beat+9.4%
    Dec 22
    		$-0.49$-0.69+28.99%Beat+31.9%
    Sep 22
    		$-0.84$-1.07+21.50%Beat-10.5%
    Jun 22
    		$-0.22N/A+56.00%Beat-166.7%
    Mar 22
    		$-0.96$-1.06+9.43%Beat-304.3%
    Dec 21
    		$-0.72$-0.73+1.37%Beat-5.9%
    Sep 21
    		$-0.76$-0.47-61.70%Miss-52.0%
    Jun 21
    		$0.33$-0.33+200.00%Beat+269.3%
    Mar 21
    		$0.47$-0.13+461.54%Beat-
    Dec 20
    		$-0.68$-0.66-3.03%Miss-
    Sep 20
    		$-0.50$-0.54+7.41%Beat-
    Jun 20
    		$-0.19N/A+57.63%Beat-

    Key Metrics

    Valuation
    P/E Ratio-68.11EV/EBITDA-3.23x
    Price/FCF57.52xFCF Yield1.74%
    Profitability
    Profit Margin-7.67%Operating Margin-11.50%
    ROE-13.70%ROIC-11.65%
    Financial Health
    Debt/Equity0.21xInterest Coverage-5.58x
    Current Ratio3.20xQuick Ratio3.17x
    Trading Statistics
    Beta0.51Avg Volume713.98K
    52-Week High$85.2552-Week Low$48.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$72.15
    SMA 20$69.50
    SMA 50$64.57
    SMA 200$68.56
    EMA 10$71.63
    EMA 20$69.49
    EMA 50$66.19
    EMA 200$64.51

    MACD

    Line: 2.75Signal: 2.66Hist: 0.08

    ADX

    ADX: 32.2+DI: 30.2-DI: 11.0

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down12.0
    PSAR$69.47

    Bollinger Bands

    Upper Band$76.95
    Lower Band$62.04
    %B Position2145%(Upper)
    Band Width0.82

    RSI (14-Day)

    Neutral
    67.5

    Momentum Oscillators

    Stoch %K80.9
    Stoch %D77.8
    Williams %R-9.5
    ROC (10d)5.1%
    Momentum3.63
    CCI (20d)95.0
    MFI (14d)69.3

    Volatility Measures

    ATR (14d)$2.81(3.8%)
    StdDev (20d)3.73
    Hist Vol36.7%(Moderate)

    Volume Flow

    VWAP$73.30
    OBV11.1M
    AD Line12.8M
    CMF (20d)0.433

    Volume Metrics

    Avg Vol (20d)708.1K
    Vol Ratio1.0x
    VWMA (20d)$69.28

    Pivot Points

    R3$73.58
    R2$72.81
    R1$72.28
    Pivot Point$71.51
    S1$70.98
    S2$70.21
    S3$69.68

    Advanced Oscillators

    TSI29.21
    Ultimate Osc67.0
    KST174.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$173.91M$162.05M$151.67M$118.70M$102.66M$78.33M$66.41M$48.12M$40.81M$27.61M$13.08M$1.87M
    Cost of Revenue$12.11M$9.40M$10.93M$8.31M$6.24M$5.21M$4.93M$3.24M$3.00M$1.65M$1.22M$377,000
    Gross Profit$161.80M$152.66M$140.74M$110.39M$96.42M$73.12M$61.48M$44.88M$37.81M$25.96M$11.86M$1.49M
    Operating Expenses$181.71M$158.78M$148.72M$124.92M$118.61M$99.40M$85.90M$70.04M$71.11M$63.64M$56.31M$42.43M
    R&D$31.01M$22.35M$18.04M$16.28M$15.59M$14.41M$16.87M$12.13M$12.32M$12.07M$13.30M$12.11M
    SG&A$150.70M$136.43M$130.68M$108.63M$103.01M$85.00M$69.03M$57.91M$58.79M$51.58M$43.01M$30.32M
    Operating Income$-19,908,000$-6,122,000$-7,976,000$-14,529,000$-22,184,000$-26,280,000$-24,421,000$-25,162,000$-33,302,000$-37,684,000$-44,450,000$-40,935,000
    Interest Income$6.51M$3.72M$3.95M$4.11M$4.23M$3.45M$3.65M$4.12M$4.13M$3.12M$2.98M$2.84M
    Interest Expense$2.16M$2.13M$2.21M$2.27M$2.24M$2.21M$2.31M$2.44M$4.05M$983,000$989,000$858,000
    Income Before Tax$-15,835,000$-4,615,000$-6,314,000$-12,585,000$-20,340,000$-25,120,000$-23,113,000$-23,420,000$-33,290,000$-35,731,000$-41,902,000$-39,148,000
    Income Tax Expense$2.72M$2.35M$0$0$0$0$0$0$0$0$0$0
    Net Income$-18,551,000$-6,967,000$-8,373,000$-12,585,000$-20,340,000$-25,120,000$-23,113,000$-23,420,000$-33,290,000$-35,731,000$-41,902,000$-39,148,000
    EBITDA$-19,785,000$-6,462,000$-8,376,000$-15,353,000$-23,439,000$-27,076,000$-25,359,000$-25,826,000$-34,325,000$-37,771,000$-43,525,000$-41,305,000
    EBIT$-20,189,000$-6,209,000$-8,050,000$-14,431,000$-22,329,000$-26,361,000$-24,448,000$-25,095,000$-33,367,000$-37,865,000$-43,891,000$-41,130,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TARS

    News

    After $3.8M sale, Tarsus (TARS) ex-officer plans more selling

    A former officer of Tarsus Pharmaceuticals, Inc. (TARS), Aziz A. Mottiwala, plans to sell 81,332 shares of common stock valued at $5.8 million, following a recent sale of 53,043 shares for $3.8 million. This information comes from a Rule 144 notice filed with the SEC, indicating the shares originate from a stock option exercise. The company currently has 43,882,996 shares of common stock outstanding.

    Stock Titan•8/25/26•
    Neutral

    Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 3.82 Million in Common Stocks

    An insider at Tarsus Pharmaceuticals (TARS.US) has proposed to sell 3.82 million common stocks, as disclosed in a recent Form 144 filing. This significant proposed sale by an insider may be of interest to current and potential investors monitoring the company's stock activity.

    Moomoo•8/20/26•
    Somewhat-Bearish

    Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares

    A former officer of Tarsus Pharmaceuticals, Aziz A. Mottiwala, plans to sell 53,043 shares of common stock, valued at approximately $3.8 million. The sale is connected to a stock option exercise and will be handled by Fidelity Brokerage Services LLC. This information was disclosed in a Form 144 SEC filing.

    Stock Titan•8/19/26•
    Neutral

    TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

    TimesSquare Capital Management LLC has acquired a new stake of $23.25 million in Tarsus Pharmaceuticals, Inc., purchasing 369,377 shares, representing a 0.86% ownership. Institutional investors now collectively own approximately 90.01% of the company, which holds a "Moderate Buy" consensus rating from analysts with an average price target of $90.50. Despite reporting quarterly revenue ahead of estimates at $173.91 million, Tarsus Pharmaceuticals experienced a wider-than-expected loss of $0.43 per share.

    MarketBeat•8/18/26•
    Somewhat-Bullish

    Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention?

    Tarsus Pharmaceuticals (TARS) shares have seen positive movement following its Q2 2026 earnings report, which indicated higher revenue, a reduced net loss, and an increased full-year sales outlook for XDEMVY. The company is currently considered 25% undervalued with a fair value of $94.11 per share, driven by anticipated revenue expansion and margin improvements, alongside pipeline diversification efforts. Investors are encouraged to analyze the company's financial data and consider potential risks associated with its reliance on XDEMVY and ongoing high costs.

    Simply Wall Street•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About TARS

    Does TARS pay dividends?
    Tarsus Pharmaceuticals Inc (TARS) does not currently pay a regular dividend.
    What is TARS's market cap?
    Tarsus Pharmaceuticals Inc (TARS) has a market capitalization of $3.15B with a current stock price of $74.24.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In